Tachyphylaxis to cisatracurium - Case reports and literature review -

Middle East Journal of Anesthesiology

Volumn 19, Issue 5, 2008, Pages 1079-1092

  Haddad, Samir ^a,b  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Cisatracurium; Critically ill; Intensive care unit; Neuromuscular blocking agents; Tachyphylaxis

Indexed keywords

ATRACURIUM; CISATRACURIUM; DRUG DERIVATIVE; NEUROMUSCULAR BLOCKING AGENT;

ADOLESCENT; ADULT; ARTIFICIAL VENTILATION; CASE REPORT; FEMALE; HUMAN; INTENSIVE CARE UNIT; MALE; MIDDLE AGED; REVIEW; TACHYPHYLAXIS; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ATRACURIUM; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; NEUROMUSCULAR BLOCKING AGENTS; RESPIRATION, ARTIFICIAL; TACHYPHYLAXIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 56049121956     PISSN: 05440440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. WAITING SM, DASTA JF: Prolonged paralysis in intensive care unit patients after the use of neuromuscular blocking agents: a review of the literature. Crit care Med; 22:884-893, 1994.
2. LACOMIS D, GIULIANI MJ, VAN COTT A, et al: Acute myopathy of intensive care: clinical, electromyographic, and pathologic aspects. Ann Neurol; 40:645-654, 1996.
3. NATES J, COOPER D, DAY B, etal: Acute weakness syndromes in critically ill patients-a reappraisal. Anaesth Intensive Care; 25:502-513, 1997.
4. DAVIS NA, RODOERS JE, GONZALEZ ER, et al: Prolonged weakness after cisatracurium infusion: a case report. Crit Care Med; 26:1290-1292, 1998.
5. MEYER KC, PRIELIPP RC, GROSSMAN JE, et al: Prolonged weakness after infusion of atracurium in two intensive care unit patients. Anesth Analg; 78:772-774, 1994.
6. LATRONICO N, FENZI F, RECUPERO D, et al: Critical illness myopathy and neuropathy. Lancet; 347:1579-1582, 1996.
7. BOLTON CF: Muscle weakness and difficulty in weaning from the ventilator in the critical care unit. Chest; 106:1-2, 1994.
8. COURSIN DB, MEYER DA, PRIELIPP RC: Doxacurium infusion in critically ill patients with atracurium tachyphylaxis. Am J Health Syst Pharm; 52:635-639, 1995.
9. FISH DN, SINGLETARY TJ: Cross-resistance to both atracurium-and vecuronium-induced NMB in a critically ill patient. Pharmacotherapy; 17:1322-1327, 1997.
10. TSCHIDA SJ, HOEY LL, NAHUM A, et al: Atracurium resistance in a critically ill patient. Pharmacotherapy; 15:533-539, 1995.
11. AMATO MB, BARBAS CS, MEDEIROS DM, etal: Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. NEngl J Med; 338:347-354, 1998.
12. RIKER RR, PICARD JT, FRASER GL: Prospective evaluation of the Sedation-Agitation Scale for adult critically ill patients. Crit Care Med; 27:1325-1329, 1999.
13. Brain Trauma Foundation, American Association of Neurological Surgeons, Joints Section on Neurotrauma and Critical Care. Povlishock JT (ed): Management and Prognosis of Severe Traumatic Brain Injury. J Neurotrauma; 17:449-627, 2000.
14. MURRAY MJ, COWEN J, DEBLOCK H, et al: Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Crit Care Med; 30(1):142-156, 2002.
15. KHUENL-BRADY KS, SPARR H, PUHRINGER F, et al: Rocuronium bromide in the ICU: dose finding and pharmacokinetics. Eur J Anaesthesiol Suppl; 11:79-80, 1995.
16. SPARR HJ, WIERDA JMKH, PROOST JH, et al : Pharmacodynamics and pharmacokinetics of rocuronium in intensive care patients. Br J Anaesth; 78:267-273, 1997.
17. MURRAY MJ, COURSIN DB, SCUDERI PE, et al: Double-blind, randomized, multicenter study of doxacurium vs. pancuronium in intensive care unit patients who require neuromuscular-blocking agents. Crit Care Med; 23:450-458, 1995.
18. KHUENL-BRADY KS, REITSTATTER B, SCHLAGER A, et al: Long-term administration of pancuronium and pipecuronium in the intensive care unit. Anesth Analg; 78:1082-1086, 1994.
19. RUDIS MI, SIKORA CP, ANGUS E, etal: Aprospective, randomized, controlled evaluation of peripheral nerve stimulation versus standard clinical dosing of neuromuscular blocking agents in critically ill patients. Crit Care Med; 25:575-583, 1997.
20. PRIELIPP RC, COURSIN DB, SCUDERI PE, et al: Comparison of the infusion requirements and recovery profiles of vecuronium and cisatracurium 51 W 89 in intensive care unit patients. Anesth Analg; 81:3-12, 1995.
21. DE WLOF AM, FREEMAN JA, SCOTT VL, et al: Pharmacokinetics and pharmacodynamic of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. Br J Anaesth; 76:624-628, 1996.
22. PEARSON AJ, HARPER NJ, POLLARD BJ: The infusion requirements and recovery characteristics of cisatracurium ar atracurium in intensive care patients. Intensive Care Med; 22:694-698, 1996.
23. BOYD AH, EASTWOOD NB, PARKER CJ, et al: Comparison of the pharmacodynamics and pharmacokinetics of and infusion of cisatracurium (51 W 89) or atracurium in critically ill patients undergoing mechanical ventilation in a intensive therapy unit. Br J Anaesth; 76:382-388, 1996.
24. NEWMAN PJ, QUINN AC, GROUNDS RM, et al: comparison of cisatracurium (51 W 89) and atracurium by infusion in critically ill patients. Crit Care Med; 25:1139-1142, 1997.
25. SCHRAMM WM, PAPOUSEK a, MICHALEK- SAUBERER A, et al: The cerebral and cardiovascular effects of cisatracurium and atracurium in neurosurgical patients. Anesth Analg; 86:123-127, 1998.
26. PRIELIPP RC, ROBINSON JC, WILSON JA, et al: Dose response, recovery, and cost of doxacurium as a continuous in neurosurgical intensive care unit patients. Crit Care Med; 25:1236-1241, 1997.
27. PRIELIPP RC, JACKSON MJ, COURSIN DB: Comparison of neuromuscular recovery after paralysis with atracurium versus vecuronium in a ICU patient with renal insufficiency. Anesth Analg; 78:775-778, 1994.
28. FREEBAIM RC, DERRICK J, GOMERSALL CD, et al: Oxygen delivery, oxygen consumption, and gastric intramucosal pH are not improved by a compuptcr-controlled, closed-loop, vecuronium infusion in severe sepsis. Crit Care Med; 25:72-77.
29. TSCHIDA SJ, GRAIJPE KJ, HOEY LL, et al: Resistance to nondepolarizing neuromuscular blocking agents. Pharmacotherapy; 16:409-418, 1996.
30. BRETT RS, SCHMIDT JH, GAGE JS, et al: Measurement of acetylcholine receptor concentration in skeletal muscle from a patient with multiple sclerosis and resistance to atracurium. Anesthesiology; 66:837-839, 1987.
31. MOORTHY SS, KRISHNA G, DIERDORF SF: Resistance to vecuronium in patients with cerebral palsy. Anesth Analg; 73:275-277, 1991.
32. SHAYEVITZ JR, MATTEO RS: Decreased sensitivity to metocurine in patients with upper motomeuron disease. Anesth Analg; 64:767-772, 1985.
33. MOORTHY SS, HILGENBERO JC: Resistance to nondepolarizing muscle relaxants in paretic upper extremities of patients with residual hemiplegia. Anesth Analg; 59:624-627, 1980.
34. IWASAKI H, NAMIKI A, OMOTE K, et al: Response differences of paretic and healthy extremities to pancuronium and neostigmine in hemiplegic patients. Anesth Analg; 64:864-866, 1985.
35. FIACCHINO F, GEMMA M, BRICCHI M, et al: Hypo-and hypersensitivity to vecuronium in a patient with Guillain-Barre syndrome. Anesth Analg; 78:187-189, 1994.
36. MARTYN JAJ, WHITE DA, GRONET GA, et al: Up-and down-regulation of skeletal muscle acetylcholine receptors: effects on neuromuscular blockers. Anesthesiology; 76:822-843, 1992.
37. YAMASHITA M, SHIGA T, MATSUKI, OYAMA T: Unusual resistance to pancuronium in severely burned patients: case reports. Can Anaesth Soc J; 29:630-631, 1982.
38. LAGASSE RS, GAGEJS, SCHARTEL SA: Acetylcholine receptors and resistance to atracurium in humans with thermal injury [abstr]. Anesth Analg; 70:S222, 1990.
39. MARATHE PH, DWERSTEG JF, PAVLIN EG, et al: Effects of thermal injury on the pharmacokinetics and pharmacodynamics of atracurium in humans. Anesthesiology; 70:752-755, 1989.
40. KIM C, FUKE N, MARTYN JAJ: Burn injury to rat increases nicotinic acetylcholine receptors in the diaphragm. Anesthesiology; 68:401-406, 1988.
41. UYAR M, HEPAGUSLAR H, UGUR G, et al: Resistance to vecuronium in burned children. Paediatr Anaesth; 9:115-118, 1999.
42. PAVLIN EG, HASCHKE RH, MARATHE PH, et al: Resistance to atracurium in thermally injured rats. Anesthesiology; 69:696-701, 1988.
43. HEPAGUSLAR H, UYAR M, UOUR G, et al: Resistance to vecuronium after immobilization. Paediatr Anaesth; 9:94-95, 1999.
44. HOGUE CW, ITANI MS, MARTYN JAJ: Resistance to d-tubocurarine in lower motor neuron injury is related to increased acetylcholine receptors at the neuromuscular junction. Anesthesiology; 73:703-709, 1990.
45. HICKEYDR, SANGWAN S, BEVAN JC: Phcnytoin-induced resistance to pancuronium. Use of atracurium infusion in management of a neurosurgical patient. Anaesthesia; 43:757-759, 1988.
46. KUMAR CM, LAWLER PG: Phenytoin-induced resistance to vecuronium. Anaesthesia; 44:263-264, 1989.
47. KIM CS, ARNOLD FJ, ITANI MS, etal: Decreased sensitivity to metocurine during long-term phenytoin therapy may be attributable to protein binding and acetylcholine receptor changes. Anesthesiology; 77:500-506, 1992.
48. HOGUE CW, WARD JM, ITANI MS, et al: Tolerance and upregulation of acetylcholine receptors follow chronic infusion of d-tubocurarine. J Appl Physiol; 72:1326-1331, 1992.
49. CHANG CC, CHUANG S, HUANG MC: Effects of chronic treatment with various neuromuscular blocking agents on the number and distribution of acetylcholine receptors in the rat diaphragm. J Physiol; 250:161-173, 1975.
50. BERG DK, HALL ZW: Increased extrajunctional acetylcholine sensitivity produced by chronic postsynaptic neuromuscular blockade. J Physiol; 244:659-676.
51. BROOKES JP, HALL ZW: Acetylcholine receptors in normal and denervated rat diaphragm muscle. II. Comparison of junctional and extrajunctional receptors. Biochemistry; 14:2100-2106, 1975.
52. GU Y, HALL ZW: Immunological evidence for a change in subunits of acetylcholine receptor in developing and denervated rat muscle. Neuron; 1:117-125, 1988.
53. COURSIN DB, KLASEK G, GOELZER SL: Increased requirements for continuously infused vecuronium in critically ill patients. Anesth Analg; 69:518-521, 1989.
54. KELLY KJ, CLARENS DM, KOHLS PR, et al: Response to pancuronium after loss of atracuriuminduced neuromuscular blockade. Ann Pharmacother; 27:862-865, 1993.